Artelo Biosciences, Inc.
ARTL
$9.35
-$0.18-1.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.62% | -1.16% | -5.78% | 4.54% | -10.62% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.74% | 123.21% | 35.80% | -45.77% | -72.20% |
| Change in Net Operating Assets | 544.31% | 490.80% | 36.80% | -64.66% | 110.06% |
| Cash from Operations | 41.98% | 21.85% | -1.74% | -6.01% | -20.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.93% | 152.23% | 121.53% | 290.71% | 198.93% |
| Cash from Investing | 20.93% | 152.23% | 121.53% | 290.71% | 198.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 82.64% | -90.84% | -80.25% | -83.74% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 201.13% | -90.84% | -80.25% | -87.00% | 364.18% |
| Foreign Exchange rate Adjustments | 20.00% | -102.33% | -113.33% | -100.00% | 128.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.49% | 92.15% | 88.29% | 138.20% | 24.44% |